PCV69 SIMPLE SENSITIVITY ANALYSIS TO ASSESS THE IMPACT OF ROUNDING OF BLOOD PRESSURE MEASUREMENTS ON ESTIMATES OF CONTROL RATES  by Ishak, KJ et al.
statin mono-therapy. Overall 55% of the patients were at target
(56% of PP and SP patients and 54% of MS patients). Multi-
variate analyses of the patient/physician questionnaire from 7
countries that contributed to the complete dataset showed that
non-adherence to LLD intake was an important determinant for
not reaching LDL-C targets (OR: 0.57; [95% CI, 0.48–0.91]).
CONCLUSION: More than 40% of European patients using
LLD are not on target for LDL-C. Measures to increase adher-
ence may have signiﬁcant impact to reach LDL-C targets.
CARDIOVASCULAR DISEASE—Methods and Concepts
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OBJECTIVES: Clinicians have a strong tendency to round blood
pressure (BP) readings, particularly to the closest multiple of ten,
even when using precise digital devices. This poses a challenge
for classifying patients as controlled in economic evaluations
when values fall on the boundary of the deﬁnition (e.g., 140/
90 mmHg), since including or excluding the boundary values will
over- or under-estimate control rates. We describe a simple
sensitivity analysis to gauge the impact of rounded readings.
METHODS: The method attempts to correct the excess number
of values ending in zero by redistributing these in the 5 mmHg
range around the observed value. Thus, a value of 140 mmHg is
replaced by a new hypothetical measurement drawn randomly
between 135–144 mmHg. The correction is made for 90% of
observations falling on the boundary since 10% would naturally
be expected to end in zero. We illustrate the method with simu-
lated data and validate by comparing the proportion below the
threshold with the true, the rounded and the corrected BPs. The
correction was applied to data from an ongoing study of a
hypertension control education program. RESULTS: A sample of
1000 random systolic BPs was generated with mean 155 and
variance 30; these “true” data were then distorted by rounding
40% of values (as observed in the study). The 30.8% in the true
data that were controlled (<140 mmHg) dropped to 28.6% after
rounding; after the correction, the proportion was 30.9%. In
time-to-control (<140/90 mmHg) analyses of the study data,
34.2% of patients had controlled BP at 6 months based on the
observed data. Replicating the analyses with corrected BPs
yielded an estimate of 41.9%. CONCLUSION: The impact of
rounding should be taken into account in analyses of BP data to
minimize bias in control rates, as well as attenuation of treatment
effect estimates that might result.
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OBJECTIVES: In real life patients are not randomly assigned to
the study groups. Thus, the results of reality may be biased by
confounders and heterogeneity. Unsuitable propensity score esti-
mators (PSEs) and explanatory techniques, which are used to
control for observed confounders, may also bias the results. The
PSEs, popular explanatory analysis techniques and the outcomes
of acute coronary heart disease (ACHD) are assessed here.
METHODS: A total of 171 Finnish ACHD patients underwent
medication, percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass grafting (CABG). In a pro-
spective 3-month period, demographics, coronary angiography
results, costs and 15D-based quality of life were collected.
Various multinomial methods including multinomial logistic
(MLRA), stereotype logistic and nested logistic regression analy-
sis as well as naive Bayes classiﬁer was used to elicit the best PSE
using the patients in the data. Ordinary least squares (OLS) RA
with and without ln-transformations as well as generalized linear
models (GLM) were used for the explanatory RA. Multiple mea-
sures (e.g. probability, likelihood, AIC, BIC, deviance, R2,
RMSE, RESET and link-test) ranked the techniques. ACHD out-
comes were reported using unadjusted, adjusted and PS adjusted
estimation. RESULTS: Generally, the best PSE in this study was
MLRA—one additional marker was the fulﬁllment of indepen-
dence of irrelevant alternatives (IIA). In explanatory analysis,
OLS worked well for the QALY effectiveness estimates, which
ranged -0.053–-0.031 for medication, -0.013–0.009 for PTCA,
and 0.010–0.036 for CABG depending on the use of adjustment/
PSE. The ln-transformed OLS gave the best ﬁt for cost data. The
Duan-smoothed estimates for the maximum cost difference were
4.6% for medication, 0% for PTCA, and 14.1% for CABG
depending on the use of adjustment/PSE. CONCLUSION: The
analyses of different PSEs and explanatory models offer tools to
assess the ﬁtness of the models. Observational studies should be
adjusted, favorably using PSE. Thus, the sensitivity analysis of
PSEs is important.
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OBJECTIVES: To evaluate the performance of statin medica-
tions from a retrospective set of prescription and lab data.
METHODS: A high-risk, hyperlipidemic population from a large
western US integrated health plan was screened to identify
patients with a six-month period of anti-hyperlipidemic absti-
nence prior to an initial statin, with at least one subsequent
LDL-C measurement following a minimum four- month period.
Statin treatment effect was evaluated over a sub-sample of
patients who did not switch or augment. Instead of discarding
observations, a combination selection/treatment regression
model was created. The effect of atorvastatin and typical 3rd tier
statins (atorvastatin and rosuvastatin) on change in LDL-C,
adherence, treatment goal attainment (<100 mg/dL), and titrata-
tion was evaluated using two-step and FIML estimators. Change
in LDL-C was estimated using a bivariate selection rule. For
binary dependent variables, two-step FGLS and FIML (trivariate
selection rule) were used. Concomitant diabetes, hypertension,
age, and gender were exogenous regressors in the outcome equa-
tion. For the decision equations, distance from goal at baseline
was included. Recursive and non-recursive decision equations
were utilized. RESULTS: There were 2724 continuously enrolled
patients meeting the initial inclusion criteria. Atorvastatin
(n = 1119) was associated with an increase (signiﬁcant, p < 0.05,
and insigniﬁcant, depending on the model) in LDL-C relative to
other statins (n = 1605). Atorvastatin was associated with a
higher insigniﬁcant probability of adherence and a higher signiﬁ-
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